The scientific advisors and founders of Apogenix are internationally renowned experts with a proven scientific track record in the fields of apoptosis as well as CD95L and TRAIL-mediated signaling pathways. 

 

 

 

Prof. Peter Krammer, M.D.

Prof. Peter Krammer, M.D., conducted ground-breaking research in the field of apoptosis. His work has been the key to understanding the signaling pathways that control this mechanism of cell death. Prof. Krammer is author of more than 400 scientific publications. Throughout his distinguished career, Prof. Krammer has received numerous awards, including the Robert Koch Prize, the German Cancer Award, the Kitasato-Behring Prize, the Avery-Landsteiner Prize, the Ernst Jung Prize, and the Order of Merit of the Federal Republic of Germany. Currently, Prof. Krammer is Head of the Division of Immunogenetics in the Tumor Immunology Program at the German Cancer Research Center (DKFZ) and member of the Board of Directors of the National Center for Tumor Diseases (NCT) in Heidelberg, Germany. 

Prof. Henning Walczak, Ph.D.

Prof. Henning Walczak, Ph.D., completed his graduate and Ph.D. theses between 1990 and 1995 in Prof. Peter Krammer’s division at the German Cancer Research Center (DKFZ) in Heidelberg, Germany. In January 1996, he joined Immunex Corporation in Seattle, WA, USA. Following his return to Germany in 1998, he became a group leader in Prof. Krammer’s division at the DKFZ before he was awarded the BioFuture Prize in 1999 and subsequently appointed head of the BioFuture group ‘Apoptosis Regulation’ at the DKFZ. In addition to his academic research activities, Prof. Walczak served as CEO/CSO for Apogenix Biotechnology AG, the predecessor of Apogenix GmbH, from 2000 to 2004. In 2007, he moved to the UK to become Professor and Chair of Tumour Immunology at Imperial College London. In January 2013, he joined University College London as Professor of Cancer Biology to take up his new role as Chair of the newly founded Centre for Cell Death, Cancer and Inflammation (CCCI) at the UCL Cancer Institute.